company background image
SURF

Surface Oncology NasdaqGM:SURF Stock Report

Last Price

US$1.76

Market Cap

US$96.1m

7D

15.8%

1Y

-76.4%

Updated

24 Jun, 2022

Data

Company Financials +
SURF fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

SURF Stock Overview

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States.

Surface Oncology Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Surface Oncology
Historical stock prices
Current Share PriceUS$1.76
52 Week HighUS$8.38
52 Week LowUS$1.37
Beta1.68
1 Month Change-1.68%
3 Month Change-37.14%
1 Year Change-76.38%
3 Year Change-37.59%
5 Year Changen/a
Change since IPO-86.80%

Recent News & Updates

May 25

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either. Despite having partnerships with big names, the stock does not move up.

May 11
News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

SURFUS BiotechsUS Market
7D15.8%10.3%6.6%
1Y-76.4%-24.4%-18.5%

Return vs Industry: SURF underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: SURF underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is SURF's price volatile compared to industry and market?
SURF volatility
SURF Average Weekly Movement12.8%
Biotechs Industry Average Movement13.0%
Market Average Movement8.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: SURF is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SURF's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201467Rob Rosshttps://www.surfaceoncology.com

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No.

Surface Oncology Fundamentals Summary

How do Surface Oncology's earnings and revenue compare to its market cap?
SURF fundamental statistics
Market CapUS$96.11m
Earnings (TTM)-US$56.72m
Revenue (TTM)US$31.06m

3.1x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SURF income statement (TTM)
RevenueUS$31.06m
Cost of RevenueUS$59.65m
Gross Profit-US$28.59m
Other ExpensesUS$28.13m
Earnings-US$56.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.04
Gross Margin-92.05%
Net Profit Margin-182.62%
Debt/Equity Ratio17.1%

How did SURF perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is SURF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SURF?

Other financial metrics that can be useful for relative valuation.

SURF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.1x
Enterprise Value/EBITDA-0.06x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SURF's PS Ratio compare to its peers?

SURF PS Ratio vs Peers
The above table shows the PS ratio for SURF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average13.1x

Price-To-Sales vs Peers: SURF is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (13.1x).


Price to Earnings Ratio vs Industry

How does SURF's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: SURF is good value based on its Price-To-Sales Ratio (3.1x) compared to the US Biotechs industry average (13.8x)


Price to Sales Ratio vs Fair Ratio

What is SURF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SURF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.1x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: SURF is expensive based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (2x).


Share Price vs Fair Value

What is the Fair Price of SURF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SURF's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SURF's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SURF's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Surface Oncology forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-0.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SURF is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SURF is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SURF is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SURF's revenue (53.2% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: SURF's revenue (53.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SURF's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Surface Oncology performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


9.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SURF is currently unprofitable.

Growing Profit Margin: SURF is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SURF is unprofitable, but has reduced losses over the past 5 years at a rate of 9.8% per year.

Accelerating Growth: Unable to compare SURF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SURF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: SURF has a negative Return on Equity (-38.59%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Surface Oncology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: SURF's short term assets ($184.3M) exceed its short term liabilities ($19.6M).

Long Term Liabilities: SURF's short term assets ($184.3M) exceed its long term liabilities ($51.1M).


Debt to Equity History and Analysis

Debt Level: SURF has more cash than its total debt.

Reducing Debt: Insufficient data to determine if SURF's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SURF has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SURF has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 12.9% each year.


Discover healthy companies

Dividend

What is Surface Oncology current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SURF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SURF's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SURF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SURF's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SURF has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Rob Ross (47 yo)

1.17yrs

Tenure

US$4,684,873

Compensation

Dr. Robert W. Ross, M.D., also known as Rob, is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Director at Obsidian Therapeutic. He served as Ch...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD4.68M) is above average for companies of similar size in the US market ($USD758.64K).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: SURF's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

Experienced Board: SURF's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.7%.


Top Shareholders

Company Information

Surface Oncology, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Surface Oncology, Inc.
  • Ticker: SURF
  • Exchange: NasdaqGM
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$96.113m
  • Shares outstanding: 54.61m
  • Website: https://www.surfaceoncology.com

Number of Employees


Location

  • Surface Oncology, Inc.
  • 50 Hampshire Street
  • 8th Floor
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/24 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.